Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
09 Mai 2024 - 2:45PM
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical
company working to achieve the first approval for an ophthalmic
formulation of bevacizumab for the treatment of retinal diseases in
the US and the EU, today announced that it will report its
financial results for second quarter fiscal year 2024 on Thursday,
May 16, 2024. Outlook Therapeutics management will host its
inaugural quarterly conference call and live audio webcast to
discuss the operational and financial results at 8:30 AM ET that
same day.
The call will be led by Russell Trenary,
President and Chief Executive Officer and Lawrence Kenyon, Chief
Financial Officer of Outlook Therapeutics. Interested participants
and investors may access the conference call by dialing (877)
407-8291 (domestic) or (201) 689-8345 (international) and
referencing the Outlook Therapeutics Conference Call. The live
webcast will be accessible on the Events page of the Investors
section of the Outlook Therapeutics website,
outlooktherapeutics.com, and will be archived for 90 days.
About Outlook Therapeutics,
Inc.
Outlook Therapeutics is a biopharmaceutical
company working to achieve FDA and European Commission approval for
the launch of ONS-5010/LYTENAVA™ (bevacizumab-vikg or bevacizumab
gamma) as the first approved ophthalmic formulation of bevacizumab
for use in retinal indications, including wet AMD, DME and BRVO. If
ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics
expects to commercialize it as the first and only FDA and/or EC
approved ophthalmic formulation of bevacizumab for use in treating
retinal diseases in the United States, EU, United Kingdom, Europe,
Japan, and other markets. As part of the Outlook Therapeutics'
multi-year commercial planning process, Outlook Therapeutics and
Cencora entered into a strategic commercialization agreement to
expand the Outlook Therapeutics’ reach for connecting to retina
specialists and their patients. Cencora will provide third-party
logistics (3PL) services and distribution, as well as
pharmacovigilance services and other services in the United States.
For more information, please visit www.outlooktherapeutics.com.
Investor
Inquiries: Jenene
ThomasChief Executive OfficerJTC Team, LLCT:
833.475.8247 OTLK@jtcir.com
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Outlook Therapeutics (NASDAQ:OTLKW)
Historical Stock Chart
Von Sep 2023 bis Sep 2024